2026. Phosphoinositide 3-kinase-based dual-target inhibitors for cancer therapy: rational design, structure-activity relationships and biological evaluation: Review paper. ADMET and DMPK. 14, (Nov. 2026). DOI:https://doi.org/10.5599/admet.3693.